25 July, 2022
Meet Pantherna Therapeutics at BIO-Europe 2022
11 January, 2022
Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs
15 November, 2021
Astellas and Pantherna Enter into Technology Evaluation Agreement for Research of mRNA-based Regenerative Medicine.
28 May, 2021
Pantherna Therapeutics to be granted 2.2 millions EFRE public funding.
12 June, 2020
Pantherna Therapeutics GmbH signs an agreement for technology evaluation with Astellas Innovation Management LLC to evaluate Pantherna’s lipid nanoparticle transport system and mRNA molecules.
02 April, 2020
Successful follow-up financing for Pantherna Therapeutics’ development programs to fight Acute Respiratory Distress Syndrome
26 March, 2020
Pantherna Therapeutics GmbH and PROVIREX Genome Editing Therapies GmbH are developing lipid-based delivery systems for mRNA-directed genome editing of lymphocytes for the treatment of HIV and other life-threatening persistent viral diseases
20 February, 2020
Pantherna Therapeutics presented at the RNA Therapeutics Conference in London, UK
08 November, 2019
Pantherna Therapeutics to present at BIO-Europe 2019
01 November, 2019
Pantherna Therapeutics to present at mRNA Health Conference 2019